Union européenne - roumain - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - celule asociate viu recombinant turcia herpes virus (rhvt/nd) exprimarea proteinei de fuziune a newcastle boli virus d-26 tulpina lentogenă - produsele imunologice pentru aves, vaccinuri virale vii - chicken; embryonated eggs - pentru imunizarea activă a 18-a zi-vechi embryonated oua de gaina sau pui de o zi pentru reducerea mortalității și a semnelor clinice cauzate de virusul bolii de newcastle și pentru reducerea mortalității, semnelor clinice și leziunilor cauzate de virusul bolii lui marek, cu un fenotip "virulent".

Union européenne - roumain - EMA (European Medicines Agency)

pharming group n.v. - uman recombinant c1-inhibitor - angioedem, ereditar - drugs used in hereditary angioedema, other hematological agents - ruconest este indicat pentru tratamentul atacurilor acute de angioedem în adulţi cu angioedemul ereditar (aee) din cauza deficienta de c1-inhibitor esterazei.

Union européenne - roumain - EMA (European Medicines Agency)

merck sharp dohme ltd - papilomavirus uman tip 6, proteina l1, papilomavirus uman tip 11 proteina l1, papilomavirus uman de tip 16 proteina l1, papilomavirus uman tip 18 proteina l1 - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vaccinuri - silgard este un vaccin utilizat la vârsta de 9 ani pentru prevenirea:leziuni genitale precanceroase (cervicale, vulvare și vaginale), premaligne leziunilor anale, cancer de col uterin și cancer anal cauzal legate de anumite oncogene de papilomavirus uman (hpv), tipurile;veruci genitale (condyloma acuminata) cauzal legate de anumite tipuri de hpv. vezi secțiunile 4. 4 și 5. 1 pentru informații importante privind datele care susțin această indicație. utilizarea de silgard ar trebui să fie în conformitate cu recomandările oficiale.

Union européenne - roumain - EMA (European Medicines Agency)

dompe farmaceutici s.p.a. - recombinant human nerve growth factor - cheratită - oftalmologice - tratamentul defectelor moderate (defecte epiteliale persistente) sau severe (ulcer corneei) keratitei neurotrofice la adulți.

Union européenne - roumain - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccinuri - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Union européenne - roumain - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porci - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Union européenne - roumain - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccinuri - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Union européenne - roumain - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - pui - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Moldavie - roumain - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

janssen-cilag international nv - vacc. covid-19 (ad26.cov2-s[recombinant]) - suspensie injectabilă - 8.92 log10 iu/dose

Union européenne - roumain - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infecții ale virusului sincițial respirator - vaccinuri - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. vezi secțiunile 4. 2 și 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.